Kolkhir, Pavel http://orcid.org/0000-0001-5380-8132
Giménez-Arnau, Ana M.
Kulthanan, Kanokvalai http://orcid.org/0000-0002-7618-821X
Peter, Jonny http://orcid.org/0000-0002-2658-0723
Metz, Martin http://orcid.org/0000-0002-4070-9976
Maurer, Marcus http://orcid.org/0000-0002-4121-481X
Article History
Accepted: 3 August 2022
First Online: 15 September 2022
Competing interests
: P.K. received speakers fees, honoraria or travel support from Novartis and Roche. A.M.G.-A. is/was a medical adviser for Uriach Pharma/Neucor, Genentech, Novartis, FAES, GSK, Sanofi–Regeneron, Amgen, Thermo Fisher Scientific, Almirall, Celldex and LEO Pharma; received research grants supported by Uriach Pharma, Novartis and Instituto Carlos III — FEDER; and participated in educational activities for Uriach Pharma, Novartis, Genentech, Menarini, LEO Pharma, GSK, MSD, Almirall, Sanofi and Avene. K.K. received grants/research support from Novartis and honoraria or consultation fees from Novartis, Menarini and Sanofi. J.P. received speakers fees, honoraria or travel support from Takeda, CSL Behring, Janssen, Novartis and Sanofi and Pharming, and educational research grants from Takeda and Novartis. M. Metz has received honoraria (advisory board, speaker) from Amgen, ArgenX, Celldex, Moxie, Novartis, Roche and Sanofi. M. Maurer is or recently was a speaker and/or adviser for and/or has received research funding from Astria, Allakos, Alnylam, Amgen, Aralez, ArgenX, AstraZeneca, BioCryst, Blueprint, Celldex, Centogene, CSL Behring, Dyax, FAES, Genentech, GIInnovation, GSK, Innate Pharma, Kalvista, Kyowa Kirin, LEO Pharma, Lilly, Menarini, Moxie, Novartis, Pfizer, Pharming, Pharvaris, Roche, Sanofi/Regeneron, Shire/Takeda, Third Harmonic Bio, UCB and Uriach.
Free to read: This content has been made available to all.